27277-03-8

Usage

Uses

Used in Organic Synthesis:
(5-Amino-1H-[1,2,4]triazol-3-yl)-methanol is used as a starting material in organic synthesis for the preparation of various pharmaceuticals, agrochemicals, and other organic compounds. Its unique structure and reactivity make it a valuable component in the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (5-Amino-1H-[1,2,4]triazol-3-yl)-methanol is used as a building block for the development of new drugs. Its potential biological activities, such as antifungal and antibacterial properties, make it a promising candidate for the treatment of various infections and diseases.
Used in Agrochemical Industry:
(5-Amino-1H-[1,2,4]triazol-3-yl)-methanol is also utilized in the agrochemical industry for the synthesis of pesticides and other agricultural chemicals. Its ability to form stable compounds with a wide range of biological activities contributes to the development of effective and environmentally friendly agrochemicals.
Used in Materials Science:
In the field of materials science, (5-Amino-1H-[1,2,4]triazol-3-yl)-methanol has been investigated for its potential use in the development of new materials, such as polymers and coordination complexes. Its versatile properties and ability to form stable structures make it a valuable component in the creation of advanced materials with unique properties and applications.
Overall, (5-Amino-1H-[1,2,4]triazol-3-yl)-methanol is a multifaceted chemical compound with a wide range of applications across various industries, including organic synthesis, pharmaceuticals, agrochemicals, and materials science. Its unique properties and potential for further research make it a valuable asset to researchers and industry professionals alike.

InChI:InChI=1/C3H6N4O/c4-3-5-2(1-8)6-7-3/h8H,1H2,(H3,4,5,6,7)

Upstream product

• 79-14-1 glycolic Acid 
• 79-17-4 aminoguanidine 
• 2582-30-1 aminoguanidine bicarbonate 

Downstream Products

• 749929-28-0 (6-chloro-[1,2,4]triazolo[1,5-a]pyrimidine-2-yl)methanol 
• 54535-00-1 (5,7-dimethyl- [1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methanol 

Relevant academic research and scientific papers

Exploration of low-melting energetic compounds: Influence of substituents on melting points

To investigate the effect of substituents on nitrate-based energetic compounds, a class of energetic compounds based on triazole nitrates were designed, synthesized, and characterized. Crystal structures of some compounds were proved by single crystal X-ray diffraction. The analysis of the melting point of each compound shows that the effect of the substituent on the melting point of the compound follows a trend of -N3 > -NO2 > -ONO2 > -NNO2. To verify the trend, we used Hirshfeld surfaces to analyze the intermolecular effects of the substituents. The compounds (3-nitro-1H-1,2,4-triazol-5-yl)methyl nitrate and (5-azido-1H-1,2,4-triazol-3-yl)methyl nitrate, were found to be potential melt cast explosive carriers or energetic plasticizers. This journal is

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).

Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same

The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1 and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula (I), and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula (I). The invention also relates to methods of preparing the compounds of formula (I).

TRIAZOLOPYRIMIDINE DERIVATIVES WHICH ARE ANGIOTENSIN II RECEPTOR ANTAGONISTS, THEIR METHODS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS IN WHICH THEY ARE PRESENT

The present invention relates to the derivatives of the formula STR1 and their tautomeric forms, as well as their addition salts, and to their use in therapeutics, especially for the treatment and prevention of cardiovascular diseases and in particular for the treatment of hypertension, cardiac insufficiency and diseases of the arterial wall, especially atherosclerosis.

Triazolo-pyrimidine intermediates

There are disclosed a β-lactam compound represented by the formula (I): STR1 wherein R1 represents an acyl group; M represents a hydrogen atom, a protective group of an eliminatable group which is easily hydrolyzable in a human body; B represents a group represented by the formula (b): STR2 where at least one of R2, R3 and R9 represent a group represented by the formula: -A-OR4 where R4 represents a hydrogen or a lower alkyl group; and A represents a straight or branched alkylene group having 1 to 6 carbon atoms; and a remaining group or groups are each independently a hydrogen atom; a cyano group; a lower alkyl group which may be substituted by a halogen atom; a carbamoyl group which may be substituted by a lower alkyl group; a cycloalkyl group; or a carboxyl group which may be substituted by a protective group of an eliminatable group which is easily hydrolyzable in a human body, and also when R9 is -A-OR4, R2 and R3 may be combined with each other to form an alkylene group having 3 to 4 carbon atoms; and Z represents a nitrogen atom or a group represented by the formula: C-R10 where R10 represents a hydrogen atom, a carboxyl group or a lower alkyl group which may be substituted by a hydroxy group or a lower alkoxy group, or its pharmaceutically acceptable salt, and a process for preparing the same, an intermediate for synthesis of the same and a medicinal composition for bacterially infectious disease therapy containing the same.

PHARMACOLOGICALLY ACTIVE GUANIDINE COMPOUNDS

The compounds are substituted thioalkyl-, aminoalkyl-and oxyalkyl-guanidines which are inhibitors of histamine activity.